Patient responses and outcomes. (A) Hematologic response by treatment cycle. (B) Percent change in the dFLC at best response. Median dFLC change during therapy was −55% (interquartile range, −31% to −78%). (C) Patient survival. Median progression-free survival (solid line) was 16 months and median overall survival (dotted line) was 26 months. (D) Overall survival according to hematologic response. Nineteen patients were responders (dotted line) and 9 were nonresponders (solid line). Median survival was 19 vs 36 months (P = .001). This is a 6-month landmark analysis. CR, complete response; NR, no response.